TNFα blockade in human diseases: An overview of efficacy and safety
- 4 October 2007
- journal article
- review article
- Published by Elsevier BV in Clinical Immunology
- Vol. 126 (1), 13-30
- https://doi.org/10.1016/j.clim.2007.08.012
Abstract
No abstract availableKeywords
This publication has 117 references indexed in Scilit:
- Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trialJournal of Dermatological Treatment, 2007
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006Annals Of The Rheumatic Diseases, 2006
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population registerArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Infliximab in the treatment of extra‐intestinal manifestations of Crohn's diseaseScandinavian Journal of Rheumatology, 2005
- Off-Label Dermatologic Uses of Anti-TNF-a TherapiesJournal of Cutaneous Medicine and Surgery, 2005
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisThe American Journal of Gastroenterology, 2004
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Rational Use of Disease-Modifying Antirheumatic DrugsDrugs, 1990